12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

Chugai said it submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) to expand the label of Avastin bevacizumab to include treatment of ovarian, fallopian tube or primary peritoneal cancer. In Japan, Avastin is approved to treat unresectable advanced or recurrent colorectal cancer, unresectable advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) and inoperable or recurrent breast cancer. Last month,...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >